-transparent.png){kind=logo}
Okadaic acid (OA), a specific protein phosphatase inhibitor, has various biological functions. To elucidate the mechanism of OA resistance, we have established a small-cell lung-cancer subline (H69/OA100) resistant to the growth-inhibitory effect of OA; this was done by using the parental cell line (H69) and increasing the concentration of OA. H69/OA100 was about 8 times more resistant to OA than H69. Intracellular retention of the fluorescent OA derivative in H69/OA100 was the same as that in H69. The catalytic activity of protein phosphatase from H69/OA100 was significantly reduced compared with that from H69. The protein phosphatase from H69/OA100 was 3.6 times more resistant to OA than that from H69. We examined the effect of OA on the activity of the immunoprecipitated protein phosphatase type I (PPI) and type 2A (PP2A) from the 2 cell lines. The PPI and PP2A from H69/OA100 showed more resistance to OA than those from H69. We next examined the effect of OA on the cell cycle of H69 and H69/OA100. In H69, G2/M block was observed at an OA concentration of 30 ng/ml whereas in H69/OA100, no G2/M block was observed at concentrations up to 100 ng/ml OA. We finally evaluated the amount of p34cdc2 kinase expression and the phosphorylation status of p34cdc2. There was no difference in p34cdc2 expression between H69 and H69/OA100 at several concentrations of OA. However, dephosphorylation of p34cdc2 was observed at 30 ng/ml OA in H69, but not in H69/OA100 up to 100 ng/ml OA. These data suggest that the resistance to OA and the resistance of the cell-cycle block to OA in H69/OA100 might be due to alteration of protein phosphatase activity.
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
April 1986,
Acta medica Okayama,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
June 1993,
Acta medica Okayama,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
August 2005,
International journal of cancer,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
December 1992,
Anti-cancer drug design,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
January 2000,
Anticancer research,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
July 2001,
Cell death and differentiation,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
June 1992,
Acta medica Okayama,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
April 1986,
Acta medica Okayama,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
October 2011,
Cancer letters,
Y Takeda, and
K Nishio, and
N Kubota, and
K Miura, and
T Morikage, and
T Ohmori, and
S Kudoh, and
H Niitani, and
N Saijo
January 2001,
TheScientificWorldJournal,
